Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
0.6560
+0.0218 (3.44%)
At close: Apr 1, 2025, 4:00 PM
0.6418
-0.0142 (-2.16%)
After-hours: Apr 1, 2025, 4:35 PM EDT

Company Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.

The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.

It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders.

The company was founded in 2010 and is based in Glen Allen, Virginia.

Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals logo
Country United States
Founded 2010
IPO Date Jul 30, 2018
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Cary Claiborne

Contact Details

Address:
4870 Sadler Road, Suite 300
Glen Allen, Virginia 23060
United States
Phone 804 487 8196
Website adial.com

Stock Details

Ticker Symbol ADIL
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001513525
CUSIP Number 00688A106
ISIN Number US00688A2050
Employer ID 80-0667150
SIC Code 2834

Key Executives

Name Position
Cary John Claiborne MBA Chief Executive Officer, President and Director
Tony Goodman Chief Operating Officer and Director
Joseph A. M. Truluck M.B.A., MBA Consultant
Vinay Shah A.C.A., M.B.A. Chief Financial Officer and Treasurer
John R. Martin J.D. Chief Legal Officer
Andrew Taubman Vice President of Corporate Development
Dr. Brigette Robertson M.D. Acting Chief Medical Officer
Abel Svitavsky CPA Controller

Latest SEC Filings

Date Type Title
Mar 21, 2025 8-K Current Report
Mar 7, 2025 8-K Current Report
Mar 4, 2025 8-K Current Report
Mar 4, 2025 10-K Annual Report
Feb 25, 2025 8-K Current Report
Jan 13, 2025 8-K Current Report
Jan 8, 2025 8-K Current Report
Dec 31, 2024 424B3 Prospectus
Dec 30, 2024 EFFECT Notice of Effectiveness
Dec 26, 2024 UPLOAD Filing